Dr. Holen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 Highland Ave
Madison, WI 53792Phone+1 608-265-1700Fax+1 608-262-1982
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1996 - 1999
Columbia University Vagelos College of Physicians and SurgeonsClass of 1996
Certifications & Licensure
IL State Medical License 2002 - 2017
WI State Medical License 2002 - 2015
Clinical Trials
- Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas Start of enrollment: 2004 Jul 01
- Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
- AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Start of enrollment: 2008 Nov 07
- Join now to see all
Publications & Presentations
PubMed
- 101 citationsPhase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid MalignanciesAmye J. Tevaarwerk, Kyle D. Holen, Dona Alberti, C. Sidor, Jamie Arnott
Clinical Cancer Research. 2009-02-15 - 17 citationsPhase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid TumorsElaine T. Lam, S. Gail Eckhardt, Wells A. Messersmith, Antonio Jimeno, Cindy L. O'Bryant
Molecular Cancer Therapeutics. 2018-01-01 - 69 citationsA Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine CarcinomaTabraiz A. Mohammed, Kyle D. Holen, Renata Jaskula-Sztul, Daniel Mulkerin, Sam J. Lubner
The Oncologist. 2011-06-01
Press Mentions
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual MeetingMay 19th, 2023- New Skin Cancer Vaccine Cuts Risk of Relapse by 44%, Study Shows—Here’s What to KnowApril 22nd, 2023
- Skin Cancer: Vaccine May Help Prevent It from ReturningApril 19th, 2023
- Join now to see all
Grant Support
- Phase II Trial Of Bevacizumab And Erlotinib In Advanced Biliary TumorsNational Center For Research Resources2007
- Phase II Study Of Bevacizumab PLUS Erlotinib In Advanced Hepatocellular CancerNational Center For Research Resources2007
- Phase II Study Of Triapine For Advanced Adenocarcinoma Of The PancreasNational Center For Research Resources2006
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
